Phase 3 clinical studies have confirmed that the gontag-releasing hormone (GnRH) agent Relugolix significantly reduces pain in women with endometriosis.

Myovant Sciences announced that a daily Relugolix combination therapy (Relugolix 40 mg combined estradiol 1.0 mg and acetic phenoxone 0.5 mg) to treat pain in women with endometriosis phase III study SPIRIT 2 reached the primary therapeutic endpoint and six secondary endpoints.
and Relugolix combination therapy is well- resistant.
Relugolix is a daily oral gontagogen release hormone (GnRH) agent that reduces the production of ovarian estradiol, which stimulates the growth of uterine fibroids and endometriosis.
analysis of the results of SPIRIT 2, 75.2% of women who received Relugolix combination therapy achieved clinically significant improvements in pain, while 30.4% of the placebo group achieved clinically significant improvements.
for menstrual pelvic pain, 66.0% of women in Relugolix combined therapy achieved clinically significant improvements, and 42.6% in the placebo group (p .lt;0.0001).
average, women who received Relugolix combined treatment decreased from 7.2 (severe pain) to 1.7 (mild pain), a decrease of 75.1 percent, according to the 11-point (0-10) digital score scale.
Myovant also announced that in another clinical study, relugolix combination therapy achieved 100 percent ovulation inhibition in 67 healthy women over an 84-day treatment period, based on the Hoogland-Skouby evaluation scale.
, 100 per cent of women resumed ovulation or menstruation after stopping the drug, with an average ovulation time of 23.5 days.
endometriosis is an inflammatory disease dependent on estrogen.
pain caused by endometriosis, initial treatment options include hormonal contraceptives and over-the-counter painkillers.
in more severe cases, GnRH astrists can be used for short-term treatment.
200 million women worldwide are affected by the disease.
.